CAXTON CORP - Q4 2020 holdings

$160 Million is the total value of CAXTON CORP's 44 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .

 Value Shares↓ Weighting
XL NewXL FLEET CORP$7,119,000300,000
+100.0%
4.44%
RZLT NewREZOLUTE INC$5,087,000424,243
+100.0%
3.17%
AJAX NewAJAX I$3,103,000250,000
+100.0%
1.93%
LUXAU NewLUX HEALTH TECH ACQUISITIONunit 11/30/2027$2,300,000200,000
+100.0%
1.43%
MRACU NewMARQUEE RAINE ACQUISITION COunit 12/01/2025$1,143,000105,500
+100.0%
0.71%
BTWN NewBRIDGETOWN HOLDINGS LTD$1,125,00072,688
+100.0%
0.70%
HMCOU NewHUMANCO ACQUISITION CORPunit 12/08/2023$942,00085,500
+100.0%
0.59%
FLACU NewFRAZIER LIFESCIENCES ACQU COunit 12/09/2025$664,00064,000
+100.0%
0.41%
SCOAU NewSCION TECH GROWTH Iunit 12/17/2025$604,00058,500
+100.0%
0.38%
PTMN NewPORTMAN RIDGE FIN CORP$571,000299,088
+100.0%
0.36%
CDLX NewCARDLYTICS INC$410,0002,869
+100.0%
0.26%
DIS NewDISNEY WALT CO$339,0001,870
+100.0%
0.21%
PYPL NewPAYPAL HLDGS INC$297,0001,267
+100.0%
0.18%
TDG NewTRANSDIGM GROUP INC$290,000469
+100.0%
0.18%
CVNA NewCARVANA COcl a$287,0001,198
+100.0%
0.18%
FICO NewFAIR ISAAC CORP$282,000552
+100.0%
0.18%
MA NewMASTERCARD INCORPORATEDcl a$281,000787
+100.0%
0.18%
V NewVISA INC$272,0001,244
+100.0%
0.17%
INTU NewINTUIT$270,000710
+100.0%
0.17%
NFLX NewNETFLIX INC$265,000491
+100.0%
0.16%
MDLZ NewMONDELEZ INTL INCcl a$255,0004,360
+100.0%
0.16%
MSFT NewMICROSOFT CORP$254,0001,142
+100.0%
0.16%
MCO NewMOODYS CORP$250,000863
+100.0%
0.16%
CHTR NewCHARTER COMMUNICATIONS INC Ncl a$251,000379
+100.0%
0.16%
GOOG NewALPHABET INCcap stk cl c$246,000140
+100.0%
0.15%
CRM NewSALESFORCE COM INC$237,0001,064
+100.0%
0.15%
FB NewFACEBOOK INCcl a$235,000860
+100.0%
0.15%
AMT NewAMERICAN TOWER CORP NEW$231,0001,027
+100.0%
0.14%
SPGI NewS&P GLOBAL INC$230,000700
+100.0%
0.14%
WHR NewWHIRLPOOL CORP$227,0001,259
+100.0%
0.14%
HLXA NewHELIX ACQUISITION CORP$182,00016,009
+100.0%
0.11%
BTWNW NewBRIDGETOWN HOLDINGS LTD*w exp 09/30/202$175,00039,773
+100.0%
0.11%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MOLECULAR TEMPLATES INC24Q2 202330.7%
STRONGBRIDGE BIOPHARMA PLC22Q3 202173.1%
GARRISON CAP INC18Q3 20209.9%
BERKSHIRE HATHAWAY INC DEL17Q3 20195.8%
EIGER BIOPHARMACEUTICALS INC17Q3 20221.7%
AGILE THERAPEUTICS INC16Q1 201855.5%
KALA PHARNACEUTICALS INC16Q4 202117.6%
CM FIN INC16Q1 20197.8%
SYNTA PHARMACEUTICALS CORP15Q2 201699.9%
CTI BIOPHARMA CORP14Q4 20218.7%

View CAXTON CORP's complete holdings history.

Latest significant ownerships (13-D/G)
CAXTON CORP Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Addex Therapeutics Ltd.February 14, 2023718,8490.9%
Cardiff Oncology, Inc.February 14, 2023983,6072.2%
Rezolute, Inc.February 14, 20231,860,5185.0%
Xeris Biopharma Holdings, Inc.February 14, 20235,973,3244.4%
CTI BIOPHARMA CORPFebruary 14, 20222,239,3002.3%
Sierra Oncology, Inc.February 14, 20221,119,3227.0%
Strongbridge Biopharma plcSold outJanuary 05, 202200.0%
SUNESIS PHARMACEUTICALS INCSold outFebruary 16, 202100.0%
Alcentra Capital CorpFebruary 14, 20201,005,0007.8%
Garrison Capital Inc.February 14, 20201,223,0967.6%

View CAXTON CORP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14

View CAXTON CORP's complete filings history.

Compare quarters

Export CAXTON CORP's holdings